Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Venrock Healthcare Capital Partners Discloses 7.1% Stake in Biocryst Pharmaceuticals Inc (BCRX)

Anders Hove and Bong Koh‘s VHCP Management owns a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), as a new filing with the US Securities and Exchange Commision showed. The 13G filing revealed that VHCP Management holds 5.24 million shares of BioCryst, which represent 7.1% of the company’s outstanding stock. The fund did not report holding shares in its last 13F filing. BioCryst Pharmaceuticals’ stock has lost more than 70% since the beginning of the year.

Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Trade (NASDAQ:BCRX) Now!

Overall, during the fourth quarter, the number of funds bullish on BioCryst among those we track inched up by one to 15. Among them, the largest stake was held by Julian and Felix Baker‘s Baker Bros. Advisors, followed by Peter Kolchinsky’s RA Capital Management, which reported stakes worth $146.7 million and $31.9 million, respectively, in their last 13F filings. Other peers with similar optimism consist of D. E. Shaw’s D E Shaw, Daniel Gold’s QVT Financial and Bihua Chen’s Cormorant Asset Management.

Moreover, it’s important to mention that several funds initiated stakes in BioCryst Pharmaceuticals in the last three months of 2015. Among them, Jim Simons’ Renaissance Technologies reported the largest new position, worth $1.5 million. Other funds with new holdings include Michael S. Weiss and Lindsay A. Rosenwald’s Opus Point Partners Management, David Costen Haley’s HBK Investments and Joel Greenblatt’s Gotham Asset Management.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Venrock Healthcare Capital Partners 0 5,241,378 0 5,241,378 5,241,378 7.1%
VHCP Co-Investment Holdings 0 5,241,378 0 5,241,378 5,241,378 7.1%
Venrock Healthcare Capital Partners II 0 5,241,378 0 5,241,378 5,241,378 7.1%
VHCP Co-Investment Holdings II 0 5,241,378 0 5,241,378 5,241,378 7.1%
VHCP Management 0 5,241,378 0 5,241,378 5,241,378   7.1%
VHCP Management II 0 5,241,378 0 5,241,378 5,241,378 7.1%
Hove, Anders 0 5,241,378 0 5,241,378 5,241,378 7.1%
Koh, Bong 0 5,241,378 0 5,241,378 5,241,378 7.1%

Page 1 of 19 – SEC Filing

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No.     )*
 
 
BioCryst Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
09058V103
(CUSIP Number)
March 16, 2016
(Date of Event Which Requires Filing of This Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨ Rule 13d-1(b)
x Rule 13d-1(c)
¨ Rule 13d-1(d)
 
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
Follow Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)
Trade (NASDAQ:BCRX) Now!
Loading...